Each year, approximately 3,000 people are diagnosed with mesothelioma in the United States. A patient’s life expectancy after being diagnosed depends on a variety of factors, including the person’s age, the type and stage of mesothelioma, and the date of diagnosis. Patients who are young and strong enough to receive surgery generally live longer than most victims, but the disease is always fatal.
The American Society of Clinical Oncology recommends the following treatment options for mesothelioma patients:
Most patients also benefit from “multimodal treatments,” which encompass a combination of standard and experimental treatment options. For example, a successful multimodal option can be surgery paired with a form of intraoperative chemotherapy.
Examples of experimental treatments include:
- Epigenetic therapy
- Gene therapy
- Photodynamic therapy
- Mesothelioma virotherapy
On May 26, 2019, the U.S. Food & Drug Administration brought hope to thousands of victims by approving Tumor Treating Fields (Novo TTF-100L), the first new treatment for malignant pleural mesothelioma since 2004. Novocure’s NovoTTF-100L System uses low-intensity electric currents to inhibit tumor growth and disrupt the division of cancer cells. During clinical trials, patients treated with the NovoTTF-100L System survived six months longer than people who only received chemotherapy treatments. Interestingly, there were no reported side effects or instances of system toxicity.
Dr. Eilon Kirson, the chief science officer at Novocure, explains that the company’s ongoing mission is to “improve patients’ survival without the toxicity you get with systemic chemotherapy” and that Novo TTF-100L “is not the cure we’re all looking for, but it means that some patients are seeing a significant benefit. It’s a jump forward. It can change the outcome of this disease, make it that must less horrific.”
This is an incredible breakthrough because only 10-20% of mesothelioma patients qualify for – and can survive – tumor-removing surgeries. Even better, this system is intended for continuous home use, meaning that patients don’t need to visit the hospital to continue their treatment program.
Have You Been Diagnosed with Mesothelioma? Schedule a Consultation Today
At Shrader & Associates, L.L.P., we are thrilled to hear about this incredible mesothelioma treatment option. As committed asbestos and mesothelioma litigators, we have a comprehensive understanding of the various physical, emotional, and financial challenges associated with this devastating disease. If you require legal representation after your diagnosis, contact our firm as soon as possible. We can help you obtain restitution that safeguards your quality of life and alleviates your financial hardships.
Contact Shrader & Associates L.L.P.at (877) 958-7920 to schedule a free consultation.